188 related articles for article (PubMed ID: 20353536)
1. Role of targeted therapy in the treatment of advanced prostate cancer.
Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
[TBL] [Abstract][Full Text] [Related]
2. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
4. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
Armstrong AJ; Febbo PG
Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
6. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
7. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
8. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approach to hormone-refractory prostate cancer.
Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
11. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
12. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
13. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
14. Management of high risk metastatic prostate cancer: the case for novel therapies.
Brand TC; Tolcher AW
J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
[TBL] [Abstract][Full Text] [Related]
15. The role of systemic cytotoxic therapy for prostate cancer.
Chang SS; Kibel AS
BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
[TBL] [Abstract][Full Text] [Related]
16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
18. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
19. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
20. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]